PDCD1 and neoplasm: To assess the ability of combination therapy to enhance tumor lymphocyte infiltration and modulate the immune-suppressive tumor microenvironment in 4T1 tumors, flow cytometry results revealed that PD-1/PD-L1 inhibitor 2 monotherapy had a negligible effect on macrophage infiltration.